Arcus Biosciences, Inc. (RCUS) Stock
NYSE · RCUS
24.85
Fundamentals
Market cap
$3.18B
Price / Earnings ratio
-6.9x
Price / Sales ratio
27.3x
Price / Book ratio
6.9x
Return on assets
-35.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
NeutralRCUSSeptember 24, 2026
Business WireNeutral
Arcus Biosciences Announces New Employment Inducement Grants
RCUS

Business Wire
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
NeutralRCUSSeptember 22, 2026
Business WireNeutral
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
RCUS

Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
NeutralRCUSSeptember 9, 2026
Business WireNeutral
Arcus Biosciences Announces New Employment Inducement Grants
RCUS

Business Wire
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
NeutralRCUSAugust 26, 2026
Business WireNeutral
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
RCUS
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral1
Buy4
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
296M196M98M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
1B902M451M0
Revenue to Profit
2025$247.0M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-353.0M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
NeutralRCUSSeptember 24, 2026
Business WireNeutral
Arcus Biosciences Announces New Employment Inducement Grants
RCUS

Business Wire
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
NeutralRCUSSeptember 22, 2026
Business WireNeutral
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
RCUS

Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
NeutralRCUSSeptember 9, 2026
Business WireNeutral
Arcus Biosciences Announces New Employment Inducement Grants
RCUS

Business Wire
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
NeutralRCUSAugust 26, 2026
Business WireNeutral
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
RCUS

Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
NeutralRCUSAugust 11, 2026
Business WireNeutral
Arcus Biosciences Announces New Employment Inducement Grants
RCUS

MarketBeat
Arcus Biosciences Q2 Earnings Call Highlights
NeutralRCUSAugust 9, 2026
MarketBeatNeutral
Arcus Biosciences Q2 Earnings Call Highlights
RCUS

Zacks Investment Research
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates
NeutralRCUSAugust 6, 2026
Zacks Investment ResearchNeutral
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates
RCUS

Business Wire
Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
NeutralRCUSAugust 5, 2026
Business WireNeutral
Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
RCUS

Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
NeutralRCUSJuly 27, 2026
Business WireNeutral
Arcus Biosciences Announces New Employment Inducement Grants
RCUS

Zacks Investment Research
SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study
NeutralRCUSJuly 23, 2026
Zacks Investment ResearchNeutral
SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study
RCUS
About Arcus Biosciences, Inc.
No description available.
SectorHealthcare
IndustryBiotechnology
Employees601
CEODr. Terry J. Rosen Ph.D.
IPO DateMar 15, 2018
HeadquartersHayward, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Terry J. Rosen Ph.D. | Co-Founder, Chairman & CEO | 1960 |
| Dr. Juan Carlos Jaen Ph.D. | Co- Founder & President | 1958 |
| Mr. Robert C. Goeltz II | Principal Financial Officer & CFO | 1973 |
| Dr. Richard A. Markus M.D., Ph.D. | Chief Medical Officer | — |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder & Member of Scientific Advisory Board | — |
| Mr. Alexander Azoy CPA | Chief Accounting Officer | 1976 |
| Dr. Jonathan Yingling Ph.D. | Chief Scientific Officer | 1969 |
| Pia Eaves | Vice President of Investor Relations & Strategy | — |
| Ms. Carolyn C. Tang J.D. | General Counsel & Corporate Secretary | 1979 |
| Holli Kolkey | Vice President of Corporate Communications | — |
Fundamentals
Valuation
Market cap$3.18B
Price-to-sales ratio27.27
Price-to-book value6.88
Price-earnings ratio-6.90
Return on Equity-69.00%
Return on Sales-152.00%
Return on Assets-35.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-3.91
Income Statement
Average volume1,605,886
EBITDA$-343.00M
1 year high (52w)$31.74
1 year low (52w)$12.15
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
5 Wall Street Analyst Ratings
BUY
80% Buy
20% Hold
0% Sell
Target price
$38.50
Est return
54.62%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +1.0 | -5.1 | +28.4 | -6.2 | ||||||||
| 2022 | -26.4 | +18.2 | -16.0 | -24.3 | -25.2 | +31.7 | +0.3 | -3.2 | +1.7 | -2.7 | +41.1 | -40.0 |
| 2023 | +7.1 | -18.6 | +4.7 | -2.1 | +11.4 | +0.0 | -2.6 | +5.1 | -15.3 | -9.1 | -4.8 | +18.9 |
| 2024 | -23.1 | +20.7 | -1.2 | -17.6 | -2.8 | -3.9 | +7.3 | +9.0 | -7.7 | -0.8 | -0.4 | -6.6 |
| 2025 | -14.7 | -17.5 | -25.2 | +13.5 | +3.6 | -11.7 | +9.2 | +15.6 | +25.8 | +46.3 | +28.3 | -8.7 |
| 2026 | -9.7 | -6.0 | -9.8 | +16.8 | -1.3 | +20.1 | -2.5 | +6.0 | -16.0 |



